Virax Biolabs GroupVRAX
13F holders, Q3 2024 (September 30)5holders −2
2new positions
4sold out
1famous investor
$1.94avg. 13F price*
At the end of Q3 2024, 5 institutions reported holding Virax Biolabs Group Ltd. (VRAX) in their 13F filings, down 2 from Q2 2024. 2 opened new positions and 4 sold out. The largest holders were Renaissance Technologies ($282K), Squarepoint Ops LLC ($79K) and UBS Group AG ($40K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Virax Biolabs Group Ltd.
- CUSIP
- G9495L125
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $101K |
| Exits | 4 | $62K |
All 13F filers, Q2 2024 → Q3 2024: 201,723 shares bought and 54,130 shares sold, net +147,593 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Renaissance Technologies | 0.00% | Add +1221.7% | 145,400 | $282K |
| Squarepoint Ops LLC | 0.00% | New | 40,620 | $79K |
| UBS Group AG | 0.00% | Add +266.5% | 20,530 | $40K |
| Jane Street Group, LLC | 0.00% | New | 11,635 | $23K |
| Headlands Technologies LLC | 0.00% | Add +311.1% | 185 | $359 |
"% of holder's portfolio" is VRAX's weight in each manager's 13F, not the share of Virax Biolabs Group Ltd. the manager owns.